ERAS · Erasca, Inc. · Metrics
$14.75
+0.01 (+0.03%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$5.15B
Shares
349.76M
Volume · Oct 5
5.49M
Avg daily vol (3M)
4.26M
ERAS metrics
52 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$14.74
Market cap
$5.15B
Price action
20 metricsPrice change (1W)
+3.4%
Price change (30D)
-9.5%
Price change (3M)
-20.2%
Price change (6M)
-17.2%
Price change (YTD)
+296.2%
Price change (1Y)
+592.0%
Trailing year
Price change (5Y)
-31.6%
52-week high
$22.47
52-week low
$2.13
Change from 52-week high
-34.4%
Change from 52-week low
+592.0%
Annualized volatility
102.0%
Annualized volatility (3M)
58.7%
Beta
1.1
RSI (14D)
41.8
Price vs SMA 50
-12.8%
Price vs SMA 200
+5.4%
Avg volume (3M)
4.26M
Relative volume
0.9
Average dollar volume
$74.10M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
349.76M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
13.8
reciprocal yield 7.3%
FCF yield
-2.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-05-08
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$302.68M
Net income (TTM)
−$287.22M
Trailing 12 months
Diluted EPS (TTM)
$-0.95
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+9.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-79.4%
Return on assets
-66.0%
Debt / equity
—
Current ratio
8.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$98.08M
Quick ratio
8.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$268.74M
Latest balance sheet
Cash & equivalents
$42.54M
Total assets
$435.05M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$98.02M
Capital expenditures (TTM)
$59,000
R&D (TTM)
$108.88M
SG&A (TTM)
—
Stock compensation (TTM)
$29.85M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
257
13F filer change QoQ
+30
Institutional ownership
82.7%
Short interest
3 metricsShort interest
9.4%
Latest settlement · 7.7 days to cover
Days to cover
7.7d
Short-squeeze score
57 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—